Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586530 · ClinicalTrials.gov registry record · NA
Telehealth and Memory Study
A NA study of Chemotherapy-related Cognitive Dysfunction, sponsored by University of Pittsburgh.
- Active
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 2
- Study locations
NCT04586530: Active NA study of Chemotherapy-related Cognitive Dysfunction, sponsored by University of Pittsburgh.
NCT04586530 is a NA study of Chemotherapy-related Cognitive Dysfunction that is active but no longer recruiting, run by University of Pittsburgh. The registered enrollment target is 220 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04586530, a NA study of Chemotherapy-related Cognitive Dysfunction, is active but no longer recruiting, sponsored by University of Pittsburgh.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall purpose of this trial is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction among (female or male) breast cancer survivors. This is a multi-center, multi-clinician randomized control trial (MAAT vs. supportive therapy attention control condition). This trial will also evaluate a sub-sample of survivors pre-and post treatment with functional magnetic resonance imaging (fMRI) in a working memory task to evaluate pre-to-post treatment brain activation patterns to elucidate underlying mechanisms of clinical therapeutic change.
Primary Outcome
The FACT-Cog is a 37-item self-report measure that uses 5- point (0-4) Likert-type ratings that produce four scales: 1) Impact on quality of life; 2) Perceived cognitive impairments; 3) Comments from others; and 3) Perceived cognitive abilities. Higher scores indicate better function and quality of life on each scale. While each scale is scored and interpreted separately, they comprise the total Fact-cog assessment. The FACT-Cog has good evidence of reliability and construct validity. We are ass
Conditions Studied
Interventions
- BEHAVIORAL Supportive Therapy (ST)
- BEHAVIORAL Memory and Attention Adaptation Training (MAAT)
Study Locations (2)
Indiana
- Indiana University - Indianapolis
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What the registry record for NCT04586530 still lists
NCT04586530 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Chemotherapy-related Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Supportive Therapy (ST) is the first listed.
NCT04586530 reports a single indexed study location in Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04586530 about?
NCT04586530 is a clinical study titled "Telehealth and Memory Study". The overall purpose of this trial is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction among (female or male) breast cancer survivors. This is a multi-center, multi-clinician ra...
What is the current status of trial NCT04586530?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2021-03-18. Estimated completion is 2026-07-31.
What conditions does trial NCT04586530 study?
This clinical trial studies the following conditions: Chemotherapy-related Cognitive Dysfunction.
What interventions are being tested in trial NCT04586530?
The interventions under investigation include: Supportive Therapy (ST) (BEHAVIORAL), Memory and Attention Adaptation Training (MAAT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04586530?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04586530 being conducted?
This trial has 2 study locations across Indiana, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04586530's enrollment target sits among peer trials
220 481st of 2000 higher than 1,516 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI